A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABBV-154 IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD): AIM-CD

Intervention/treatment:
ABBV-154
Medical condition:
CROHN'S DISEASE
Protocol code:
M20-371
Control number:
256679
Status:
Closed
Approved:
November 12, 2021
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT05068284
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Medical Services
Organization
AbbVie
Phone:
800-633-9110
Sponsor
ABBVIE CORPORATION

Locations

Alberta

Gastroenterology and Internal Medicine Research Institution /ID# 233831
Edmonton, Alberta, T5R 1W2
University of Calgary /ID# 233838
Calgary, Alberta, T2N 4Z6

Nova Scotia

QE II Health Sciences Centre /ID# 233839
Halifax, Nova Scotia, B3H 1V7

Ontario

London Health Sciences Center- University Hospital /ID# 234058
London, Ontario, N6A 5W9
Scott Shulman Medicine Professional Corporation /ID# 239567
North Bay, Ontario, P1B 2H3
Toronto Digestive Disease Associates, Inc. /ID# 234143
Vaughan, Ontario, L4L 4Y7
Toronto Immune and Digestive Health Institute Inc /ID# 234142
North York, Ontario, M6A 3B4

Results

See the results from the trial NCT05068284. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?